{"name":"Rapa Therapeutics LLC","slug":"rapa-therapeutics-llc","ticker":"","exchange":"","domain":"rapallc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Chemotherapy Prior to RAPA-201 Therapy","genericName":"Chemotherapy Prior to RAPA-201 Therapy","slug":"chemotherapy-prior-to-rapa-201-therapy","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Chemotherapy Prior to RAPA-201 Therapy","genericName":"Chemotherapy Prior to RAPA-201 Therapy","slug":"chemotherapy-prior-to-rapa-201-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQV19SSmJGenRyTUxPR0twOHlwei1YNTVYUWNYVi1NaGoxU3NpYUdLQjNpamFnR3lKN3JXelRkeHdFWWdDeGRHUkg4YmNkcHFjLWhUNDJlVW5fX0xtQW1VUnVVdHA0d1l2X3RhTDNmUHJqUl9UUTJqZEpBVzdhLTI5SEVsS3lsODNxUG04OWdfUDE4T0hvMk9xUkVqaVNPd0dSOTMxb3U4YTZXTEttQ280SXRvek1uekJfVmZLYTFJWERNYkhoX0hyaWxHMm1Zcl9jcW1fekFyZ3I3MzNWbjlFVThCZG5aMHNDV1I3czZyZ19QZGR2cmlaNXJFSE9KVV9TejdEYXZaUEN3S1ZMNkNnR0JLSnFabXJMY3RIZmttTWx1MXVmZ0hLS0MwdE9aU2lxR2ZwajlqMG9mRzhFSEgwUw?oc=5","date":"2025-12-09","type":"pipeline","source":"PR Newswire","summary":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOQnVMZjBIMnRadVZZWkJTZGdNU3E0YkV6blU4ZTZwbEVuV09udVJvZDEzTFRmcjhjb1NhRDctNktxUHA1SmViU0xNYVNZejhOUS1XeFJVR3A2VzQ2MjAweE9EdHJJVzhMV0cxYUM0eF9CV0drVXhwbmQ2bHF2YzE5U2M5V0I5cUhtMXdFM1NjckE1dGhXR21uMzBfeWtaWEtkMkdkZnFZd1NDc3NldFFmVndCUEF3elRtNUJGMUpkLWF0UV9ITHpTOURBVS1KY3ZTN24tMWMzMlEyaGdVUXlLZ2JFRE5wWHhUODVFRGxfQlJTSXVkeTMtclBIbXVSQjJEdGxOSHFYdmxvRmtYUDN5RDdIY1NaRmZhQlpORm1oeXo1alRXbzh6SVUzT25SUlhWN3RXMkJJX1dFS2MyTF8wVjZzVGRqNkU?oc=5","date":"2025-10-23","type":"pipeline","source":"PR Newswire","summary":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight - PR Newswire","headline":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"GlobeNewswire","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - GlobeNewswire","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQYmtyV3JOSE1tU19HWE1HQzgwRVhwYkJNUG1iLS1lQmtONW9BNGhFWDFUNmJVVW1ObU5ZYjhBZHExaDg5bjdtZjRvbERUbFdwVWU2NFZNWDdxbG1VVnVtZzFZUTMwa3d5UkMxZndxYWE5dHpNanJwUi1uTThCei1QNDhmX0JPWHhONV90bmhSazMtX1lDb0pzN2NRbTBpaUVoRTVBYXg3YkZ3SHVlZnRIZXVaRUtDZGNmUFlpTkpVY0hSSF80RjhKMVFUTVctelBNMGEtZVJTbk40Z251Vy13akJRRktuNU5qN3BrdjZmVlFHVnl4YnFNQ251cmc1Z01ha1M0REdKX29rYU02dFE?oc=5","date":"2025-07-24","type":"pipeline","source":"PR Newswire UK","summary":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight - PR Newswire UK","headline":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOLXMtZlFJTmRmZVZ4YXA5bEdrVHpwTXMzR1VJallzekU0ZXhmUERqOTctUzh1b3FycmM2Ul9hSDYyUF9lSDZheDh6RTc3ZWF6WXlYaWpSZlFtc01IbFRvX3FLeVVqNzFDZmh1elZwR2F2QmR4RUh4WlJFWEQ1X3dGR3J3bTJ4Q2xkOHZXdVFRbE1rVzU3WktXRlE3T1RJUXQ3UUVmcXJMRUswYlYwRmVhM3JWekUxWWp6RnhTLVA3Rm1NSUJlM2pDclpFbThVMDFrOTFzeWUtaDMtVWFsZkdoMUVyVHpEdTVRakVwbFl6SXMwYjZUS3FRR04xYnNWMEk?oc=5","date":"2025-03-24","type":"pipeline","source":"PR Newswire UK","summary":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight - PR Newswire UK","headline":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNR3JCQnhRWFJKakk0Ykwxd25Za2xkR2lvY1ZPbGNUR29BaDZiaHZ5TWRZbmxUUm9RaXNPWFNjaFduVUw5NHBZRmZWQ01KYnUwNlVlRzg3UFVZcWJ4eFpzNHk1VGZLNDd4OWwzUllQRkIyZFNsVzB5UDBNd3Q3OGFMQllCR2NDczdtaXhETmhhM0swQ2oxT1NRRnlvdkRQbzRGLWFJX3BqTXRXcHQya3ctdFJEYlc0YlAwdFo0bW1TMFNTQUhSb01scmI2SFYwN3RISDhRUU9yazBLWklLMU9nbEJINGdaa3QtdTh3d0dYdHVnY3R1b2FEZDFWcGk2YkdqX25yOVVNUC1xOVRVWDVKcl80NGgwc0ZwZW9MLUJLYjFmWkl6T1NOT1hXQ1h4eVlNNTVLVU9pWDB4bFBLVUdiSEMzT0wyZ0ZVMERyTmdYanlXWGhwbGc?oc=5","date":"2024-11-13","type":"trial","source":"GlobeNewswire","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOLTNGclp3R1k1Ql95djVkdTRCRG1mbmlmSDhFTm52MlJGZjdaNG9qU1VfbWxyUUVoOWs3aUJvUUY2M3o4bEtfUExtVXNOY1F0MUU3MzRWbFRSYmZMb0V2eEJuUnNTU1cxQUVFbXZieW1TQmxXRWxuUDRtZlM2allWeUpNQlVvN0gyNHNaSE9CTjQ0TE84ZTJJT0tlSlQtX0FCQWNqMXdhMElMa1lRdDgtZDRRNU84U1otT2ZCbXdEekttb3FKSFNZbnIxRndueUw4S0d4OTR5V3BpNkV0dTNTRzVMM2oxVGxrd1p3TFZCZmNpdXIyZGJkWm1xOW83aDM0UFV2WUM3cTdWOHVrUDg2VHJqcC1YNmxmbWl4VmlhNjlKYkZHMXc?oc=5","date":"2024-11-11","type":"trial","source":"PR Newswire","summary":"NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE43NVFqNnczYXFqVDQ5Q3NjZnUtWEdrSjRUZzRjemxfZHJDcnJfZDQ4S0EzQ1FuNUd5dWtaLTdMVEl2TEk5cE1LRHBhUFpKUjlKXzA0Y3BEWTA4dWgzLUhyRjJnUHZLYk1Ma2N3TFhLZVZGbzZvTWtCZ1lyZw?oc=5","date":"2024-04-30","type":"trial","source":"Clinical Trials Arena","summary":"Trials to watch: Four ALS drugs to keep an eye on - Clinical Trials Arena","headline":"Trials to watch: Four ALS drugs to keep an eye on","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE51Sm9iTVMzRmhXYzE0ek9UbjNWNzhDd2hvd2J5QU5EeWYtcVFoc2hvY2tDOTNQRkZNMkhROEVVMkMwQVpMSTEtTTZ1bmhfazQ0TE5FSTNQTlR3OS1ja3Y0?oc=5","date":"2023-11-15","type":"pipeline","source":"nature.com","summary":"Rapa’s epigenetic reprogramming creates T cell therapies for solid tumors and neurodegeneration - nature.com","headline":"Rapa’s epigenetic reprogramming creates T cell therapies for solid tumors and neurodegeneration","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}